NOT KNOWN DETAILS ABOUT MBL77

In addition to ibrutinib, clients with M-CLL, devoid of TP53 aberrations and in shape ample to tolerate FCR therapy, should still be great candidates for the latter, with the profit remaining that this therapy can be done in 6 months while ibrutinib needs to be taken indefinitely. This feature could well be especially beneficial for non-compliant c